Margaret A. Highland, DVM Washington State University
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Engineering the Genome of Minimal Bacteria Using CRISPR/Cas9 Tools Iason Tsarmpopoulos
Engineering the genome of minimal bacteria using CRISPR/Cas9 tools Iason Tsarmpopoulos To cite this version: Iason Tsarmpopoulos. Engineering the genome of minimal bacteria using CRISPR/Cas9 tools. Mi- crobiology and Parasitology. Université de Bordeaux, 2017. English. NNT : 2017BORD0787. tel- 01834971 HAL Id: tel-01834971 https://tel.archives-ouvertes.fr/tel-01834971 Submitted on 11 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE Science de la vie et de la Santé SPÉCIALITÉ Microbiologie and Immunologie Par Iason TSARMPOPOULOS Ingénierie de génome de bactéries minimales par des outils CRISPR/Cas9 Sous la direction de : Monsieur Pascal SIRAND-PUGNET Soutenue le jeudi 07 décembre 2017 à 14h00 Lieu : INRA, 71 avenue Edouard Bourlaux 33882 Villenave d'Ornon salle Amphithéâtre Josy et Colette Bové Membres du jury : Mme Cécile BEBEAR Université de Bordeaux et CHU de Bordeaux Président Mme Florence TARDY Anses-Laboratoire de Lyon Rapporteur M. Matthieu JULES Institut Micalis, INRA and AgroParisTech Rapporteur M. David BIKARD Institut Pasteur Examinateur M. Fabien DARFEUILLE INSERM U1212 - CNRS UMR 5320 Invité Mme Carole LARTIGUE-PRAT INRA - Université de Bordeaux Invité M. -
Examining the Risk of Disease Transmission Between Wild Dall's
Examining the Risk of Disease Transmission between Wild Dall’s Sheep and Mountain Goats, and Introduced Domestic Sheep, Goats, and Llamas in the Northwest Territories Prepared for: The Northwest Territories Agricultural Policy Framework and Environment and Natural Resources Government of the Northwest Territories, Canada August 20, 2005 Examining the Risk of Disease Transmission between Wild Dall’s Sheep and Mountain Goats, and Introduced Domestic Sheep, Goats, and Llamas in the Northwest Territories Elena Garde 1,2 , Susan Kutz 1,3 , Helen Schwantje 4, Alasdair Veitch 5, Emily Jenkins 1,6 , Brett Elkin 7 1 Research Group for Arctic Parasitology and the Canadian Cooperative Wildlife Health Centre, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK, S7N 5B4. 2 Associate Wildlife Veterinarian, Biodiversity Branch, Ministry of Environment, PO Box 9338, Stn Prov Govt, 2975 Jutland Road, Victoria, BC, V8W 9M1, (250) 953-4285 [email protected] 3 Associate Professor, Faculty of Veterinary Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary AB, T2N 4N1 Ph: (306) 229-6110 4 Wildlife Veterinarian, Biodiversity Branch, Ministry of Environment, PO Box 9338, Stn Prov Govt, 2975 Jutland Road, Victoria, BC, V8W 9M1, (250) 953-4285 [email protected] 5 Supervisor, Wildlife Management, Environment and Natural Resources, Sahtu Region, P.O. Box 130, Norman Wells, NT X0E 0V0, Ph: (867) 587-2786; Fax: (867) 587-2359 [email protected] 6 Wildlife Disease Specialist / Research Scientist, Canadian Wildlife Service, 115 Perimeter Rd. Saskatoon, SK S7N 0X4 (306) 975-5357, (306) 966-7246 7 Disease & Contaminants Specialist, Environment and Natural Resources, 500 – 6102 50 th Ave. -
Genomes Published Outside of SIGS, June
Standards in Genomic Sciences (2011) 5:154-167 DOI:10.4056/sigs.2324675 Genome sequences of Bacteria and Archaea published outside of Standards in Genomic Sciences, June – September 2011 Oranmiyan W. Nelson1 and George M. Garrity1 1Editorial Office, Standards in Genomic Sciences and Department of Microbiology, Michigan State University, East Lansing, MI, USA The purpose of this table is to provide the community with a citable record of publications of ongoing genome sequencing projects that have led to a publication in the scientific literature. While our goal is to make the list complete, there is no guarantee that we may have omitted one or more publications appearing in this time frame. Readers and authors who wish to have publications added to this subsequent versions of this list are invited to provide the bib- liometric data for such references to the SIGS editorial office. Phylum Crenarchaeota Phylum Euryarchaeota Pyrococcus yayanosii CH1, sequence accession CP002779 [1] Methanocella paludicola, sequence accession AP011532 [2] Halorhabdus tiamatea, sequence accession AFNT00000000 [3] Thermococcus sp. Strain 4557, sequence accession CP002920 [4] Phylum Chloroflexi Phylum Proteobacteria Ralstonia solanacearum strain Po82, sequence accession CP002819 (chromosome) and CP002820 (megaplasmid) [5 Desulfovibrio alaskensis G20, sequence accession CP000112 [6] Methylophaga aminisulfidivorans MPT, sequence accession AFIG00000000 [7] Acinetobacter sp. P8-3-8, sequence accession AFIE00000000 [8] Sphingomonas strain KC8, sequence accession AFMP01000000 -
A Pilot Study of the Effects of Mycoplasma Ovipneumoniae Exposure on Domestic Lamb Growth And
bioRxiv preprint doi: https://doi.org/10.1101/459628; this version posted November 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Full title: 2 A pilot study of the effects of Mycoplasma ovipneumoniae exposure on domestic lamb growth and 3 performance. 4 5 Thomas E. Besser1*, Jessica Levy1, Melissa Ackerman2, Danielle Nelson1, Kezia Manlove3, Kathleen A. 6 Potter1, Jan Busboom4, Margaret Benson4 7 8 Short title: 9 Sub-clinical Mycoplasma ovipneumoniae infection 10 11 1 Department of Veterinary Microbiology and Pathology, Washington State University College of 12 Veterinary Medicine, Pullman WA, United States of America 13 2 Department of Veterinary Clinical Sciences, Washington State University College of Veterinary 14 Medicine, Pullman WA, United States of America 15 3 Department of Wildland Resources, Utah State University College of Natural Resources, Logan UT, 16 United States of America 17 4 Department of Animal Sciences, Washington State University College of Agricultural, Human, and 18 Natural Resource Sciences, Pullman WA, United States of America. 19 * Corresponding author 20 E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/459628; this version posted November 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. -
Mycoplasma Ovipneumoniae Rotter ML, Hirschl AM
RESEARCH LETTERS Figure. Direct examination with dark-field microscopy of specimens from a patient with agammaglobulinemia who had Spiroplasma apis infection, France. A) Helical and motile bacteria in blood culture. B) Elongated and coccoid bacteria in joint fluid. C) Helical and motile bacteria in culture from joint fluid in modified SP4 broth medium. Scale bar indicates 10 µm. than honeybees. The insect stings in this patient are a likely 7. Mueller NJ, Tini GM, Weber A, Gaspert A, Husmann L, gateway of the reported infection. Bloemberg G, et al. Hepatitis from Spiroplasma sp. in an immunocompromised patient. Am J Transplant. 2015;15:2511–6. In summary, clinicians and microbiologists should be http://dx.doi.org/10.1111/ajt.13254 aware of fastidious organisms in atypical infections in im- 8. Lorenz B, Schroeder J, Reischl U. First evidence of an endogenous munocompromised patients. Our findings indicate a need Spiroplasma sp. infection in humans manifesting as unilateral for prolonged culture on specific agar on all joint fluids in cataract associated with anterior uveitis in a premature baby. Graefes Arch Clin Exp Ophthalmol. 2002;240:348–53. patients with agammaglobulinemia and targeted molecular http://dx.doi.org/10.1007/s00417-002-0453-3 methods to identify S. apis organisms. 9. Aquilino A, Masiá M, López P, Galiana AJ, Tovar J, Andrés M, et al. First human systemic infection caused by Spiroplasma. J Clin Microbiol. 2015;53:719–21. http://dx.doi.org/10.1128/JCM.02841-14 Acknowledgments We thank Anne Laurence Thomi Georgelin, who referred the Address for correspondence: Olivier Lortholary, Necker-Enfants Malades patient to the Necker-Pasteur Center for Infectious Diseases and University Hospital, 149 rue de Sevre 75743, Paris CEDEX, France; Tropical Medicine; Valérie Zeller for the management of septic email: [email protected] polyarthritis; and Philippe Lanotte and Marie-Pierre Dubrana, who participated in molecular analysis. -
Attachment 1 .PLOS ONE
Attachment 1 .PLOS ONE CORRECTION Correction: Exposure of bighorn sheep to domestic goats colonized with Mycoplasma ovipneumoniae induces sub-lethal pneumonia Thomas E. Besser, E. Frances Cassirer, Kathleen A. Potter, William J. Foreyt Tn response to queries raised after publication, the authors, the authors’ institution (Office of Research Assurance, Washington State University) and a member of PLOS ONE’s Editorial Board have reviewed the findings in this article, and as a consequence the authors provide an update to the Competing Interests statement and clarifications regarding the results: The competing interests declaration is updated to acknowledge additional sources of fund ing received by the authors. This specific study was supported by funding competitively awarded by the Wild Sheep Foundation and by revenue from the WSU Rocky Crate Endow ment for Wild Sheep Disease Research. Additional research funding for the authors’ bighorn sheep pneumonia-related research has been received from the US Department of Agriculture (including the Animal Plant Health Inspection Service and the US Forest Service), the US Geo logic Survey, numerous chapters and affiliates of the Wild Sheep Foundation, and the WSU Fowler Emerging Infectious Diseases endowment. Regarding the pneumonia diagnosis reported in the article, the authors re-assessed the pri mary data and solicited and received a second opinion from a veterinary pathologist at Wash ington Animal Disease Diagnostic Lab (WADDL) unassociated with the original project. Following this reassessment, the authors confirmed the descriptions and diagnoses as reported in the article, but they noted that the consulted pathologist advised, “some pathologists might describe the histopathologic lesions seen in the least severely affected animal as ‘bronchiolitis’ rather than ‘pneumonia’ due to the preponderance of that lesion in that animal”. -
( 12 ) United States Patent
US009956282B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,956 , 282 B2 Cook et al. (45 ) Date of Patent: May 1 , 2018 ( 54 ) BACTERIAL COMPOSITIONS AND (58 ) Field of Classification Search METHODS OF USE THEREOF FOR None TREATMENT OF IMMUNE SYSTEM See application file for complete search history . DISORDERS ( 56 ) References Cited (71 ) Applicant : Seres Therapeutics , Inc. , Cambridge , U . S . PATENT DOCUMENTS MA (US ) 3 ,009 , 864 A 11 / 1961 Gordon - Aldterton et al . 3 , 228 , 838 A 1 / 1966 Rinfret (72 ) Inventors : David N . Cook , Brooklyn , NY (US ) ; 3 ,608 ,030 A 11/ 1971 Grant David Arthur Berry , Brookline, MA 4 ,077 , 227 A 3 / 1978 Larson 4 ,205 , 132 A 5 / 1980 Sandine (US ) ; Geoffrey von Maltzahn , Boston , 4 ,655 , 047 A 4 / 1987 Temple MA (US ) ; Matthew R . Henn , 4 ,689 ,226 A 8 / 1987 Nurmi Somerville , MA (US ) ; Han Zhang , 4 ,839 , 281 A 6 / 1989 Gorbach et al. Oakton , VA (US ); Brian Goodman , 5 , 196 , 205 A 3 / 1993 Borody 5 , 425 , 951 A 6 / 1995 Goodrich Boston , MA (US ) 5 ,436 , 002 A 7 / 1995 Payne 5 ,443 , 826 A 8 / 1995 Borody ( 73 ) Assignee : Seres Therapeutics , Inc. , Cambridge , 5 ,599 ,795 A 2 / 1997 McCann 5 . 648 , 206 A 7 / 1997 Goodrich MA (US ) 5 , 951 , 977 A 9 / 1999 Nisbet et al. 5 , 965 , 128 A 10 / 1999 Doyle et al. ( * ) Notice : Subject to any disclaimer , the term of this 6 ,589 , 771 B1 7 /2003 Marshall patent is extended or adjusted under 35 6 , 645 , 530 B1 . 11 /2003 Borody U . -
Isolation and Molecular Characterization of Mycoplasma Spp
Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Available at www.veterinaryworld.org/Vol.12/May-2019/6.pdf Open Access Isolation and molecular characterization of Mycoplasma spp. in sheep and goats in Egypt Mounier M. Abdel Halium1, Fayez A. Salib1, S. A. Marouf2 and Emil S. Abdel Massieh1 1. Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt; 2. Department of Microbiology and Mycology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt. Corresponding author: Emil S. Abdel Massieh, e-mail: [email protected] Co-authors: MMAH: [email protected], FAS: [email protected], SAM: [email protected] Received: 04-12-2018, Accepted: 15-03-2019, Published online: 13-05-2019 doi: 10.14202/vetworld.2019.664-670 How to cite this article: Abdel Halium MM, Salib FA, Marouf SA, Abdel Massieh ES (2019) Isolation and molecular characterization of Mycoplasma spp. in sheep and goats in Egypt, Veterinary World, 12(5): 664-670. Abstract Background and Aim: Different species of Mycoplasma are associated with many pathological problems in small ruminants including respiratory manifestation, this problem results in significant losses, especially in African countries. This study aimed to (I) study some epidemiological aspects of Mycoplasma species infections in Egyptian sheep and goats at Giza Governorate, (II) diagnosis of Mycoplasma species affections using bacterial isolation and identification, (III) apply the polymerase chain reaction (PCR) for typing of different Mycoplasma species, and (IV) illustrate the phylogenetic tree for the isolated Mycoplasma species and other species from GenBank using the purified PCR product. Materials and Methods: A total of 335 samples were collected from sheep and goats from Giza Governorate in Egypt as 142 nasal swabs from clinically affected animals, 167 pneumonic lungs, 18 samples from tracheal bifurcation, and 8 samples by bronchial wash were cultured on pleuropneumonia-like organisms (PPLOs) media for cultivation of Mycoplasma species. -
2017 National Veterinary Scholars Symposium 18Th Annual August 4
2017 National Veterinary Scholars Symposium 18th Annual August – 4 5, 2017 Natcher Conference Center, Building 45 National Institutes of Health Bethesda, Maryland Center for Cancer Research National Cancer Institute with The Association of American Veterinary Medical Colleges https://www.cancer.gov/ Table of Contents 2017 National Veterinary Scholars Symposium Program Booklet Welcome .............................................................................................................................. 1 NIH Bethesda Campus Visitor Information and Maps .........................................................2 History of the National Institutes of Health ......................................................................... 4 Sponsors ............................................................................................................................... 5 Symposium Agenda .......................................................................................................6 Bios of Speakers ................................................................................................................. 12 Bios of Award Presenters and Recipients ........................................................................... 27 Training Opportunities at the NIH ...................................................................................... 34 Abstracts Listed Alphabetically .......................................................................................... 41 Symposium Participants by College of Veterinary Medicine -
Post-Translational Protein Deimination Signatures in Plasma and Plasma Evs of Reindeer (Rangifer Tarandus)
biology Article Post-Translational Protein Deimination Signatures in Plasma and Plasma EVs of Reindeer (Rangifer tarandus) Stefania D’Alessio 1, Stefanía Thorgeirsdóttir 2, Igor Kraev 3 , Karl Skírnisson 2 and Sigrun Lange 1,* 1 Tissue Architecture and Regeneration Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK; [email protected] 2 Institute for Experimental Pathology at Keldur, University of Iceland, Keldnavegur 3, 112 Reykjavik, Iceland; [email protected] (S.T.); [email protected] (K.S.) 3 Electron Microscopy Suite, Faculty of Science, Technology, Engineering and Mathematics, Open University, Milton Keynes MK7 6AA, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)207-911-5000 (ext. 64832) Simple Summary: Reindeer are an important wild and domesticated species of the Arctic, Northern Europe, Siberia and North America. As reindeer have developed various strategies to adapt to extreme environments, this makes them an interesting species for studies into diversity of immune and metabolic functions in the animal kingdom. Importantly, while reindeer carry natural infections caused by viruses (including coronaviruses), bacteria and parasites, they can also act as carriers for transmitting such diseases to other animals and humans, so called zoonosis. Reindeer are also affected by chronic wasting disease, a neuronal disease caused by prions, similar to scrapie in sheep, mad cows disease in cattle and Creutzfeldt-Jakob disease in humans. The current study assessed a specific protein modification called deimination/citrullination, which can change how proteins Citation: D’Alessio, S.; function and allow them to take on different roles in health and disease processes. -
Biosafety Guidelines for Contained Use of Genetically Modified Microorganisms at Pilot and Industrial Scales
Biosafety Guidelines for Contained Use of Genetically Modified Microorganisms at Pilot and Industrial Scales TECHNICAL BIOSAFETY COMMITTEE (TBC) NATIONAL CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (BIOTEC) NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (NSTDA) MINISTRY OF SCIENCE AND TECHNOLOGY (MOST) 2015 Biosafety Guidelines for Contained Use of Genetically Modified Microorganisms at Pilot and Industrial Scales TECHNICAL BIOSAFETY COMMITTEE (TBC) NATIONAL CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (BIOTEC) NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (NSTDA) MINISTRY OF SCIENCE AND TECHNOLOGY (MOST) 2015 Biosafety Guidelines for Contained Use of Genetically Modified Microorganisms at Pilot and Industrial Scales Technical Biosafety Committee National Center for Genetic Engineering and Biotechnology National Science and Technology Development Agency (NSTDA) © National Center for Genetic Engineering and Biotechnology 2015 ISBN : 978-616-12-0386-3 Tel : +66(0)2-564-6700 Fax : +66(0)2-564-6703 E-mail : [email protected] URL : http://www.biotec.or.th Printing House : P.A. Living Printing Co.,Ltd 4 Soi Sirintron 7 Road Sirintron District Bangplad Province Bangkok 10700 Tel : +66(0)2-881 9890 Fax : +66(0)2-881 9894 Preface Genetically Modified Microorganisms (GMMs) were first used in B.E. 2525 to produce insulin in industrial medicine. Currently, GMMs are used in various industries, such as the food, pharmaceutical and bioplastic industries, to manufacture a number of important consumer products. To ensure operator and environmental safety, the Technical Biosafety Committee (TBC) of the National Center for Genetic Engineering and Biotechnology (BIOTEC), the National Science and Technology Development Agency (NSTDA), has prepared guidelines for GMM work, publishing “Biosafety Guidelines for Contained Use of Genetically Modified Microorganisms at Pilot and Industrial Scales” in B.E. -
WO 2014/121298 A2 7 August 2014 (07.08.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/121298 A2 7 August 2014 (07.08.2014) P O P C T (51) International Patent Classification: VULIC, Marin; c/o Seres Health, Inc., 161 First Street, A61K 39/02 (2006.01) Suite 1A, Cambridge, MA 02142 (US). (21) International Application Number: (74) Agents: HUBL, Susan, T. et al; Fenwick & West LLP, PCT/US2014/014738 Silicon Valley Center, 801 California Street, Mountain View, CA 94041 (US). (22) International Filing Date: 4 February 2014 (04.02.2014) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/760,584 4 February 2013 (04.02.2013) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/760,585 4 February 2013 (04.02.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/760,574 4 February 2013 (04.02.2013) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/760,606 4 February 2013 (04.02.2013) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 61/926,918 13 January 2014 (13.01.2014) us TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: SERES HEALTH, INC.